Achieved revenue of $4.7 million and $13.8 million for the three and nine months ended September 30, 2018, respectively, which represents a 26% and 101% increase over the same periods in 2017, respectively.

Announced three amendments to the second PDP Program (SOW Two) under the Master Assay Development, Commercialization and Manufacturing Agreement (the Governing Agreement) with QIAGEN Manchester Limited (QML). Development activities for the clinical trial assay have been completed, and the amendments relate to the next phase development activities, including the use of the investigational use only (IUO) assay developed in the initial-phase in a retrospective clinical trial and in additional disease indications.

Entered into an amendment to the third PDP Program (SOW Three) under the Governing Agreement with QML. Initial assay development activities under SOW Three are complete, and the amendment provides for the development of an IUO assay, subsequent retrospective testing of clinical trial samples, design verification and, subject to satisfactory achievement of relevant performance and regulatory milestones, regulatory submission in the US and EU necessary for the commercialization of a companion diagnostic assay for a corresponding pharmaceutical company drug.

Launched the HTG EdgeSeq Precision Immuno-Oncology Panel and began delivery of orders to translational and clinical researchers working in the field of cancer immunology and/or cancer immunotherapy. This research use only profiling panel provides a large, comprehensive set of genes involved in the host immune response to tumors.

Announced the pre-launch introduction of the new HTG EdgeSeq Mouse miRNA Whole Transcriptome Assay (WTA) with product availability for shipment expected in the fourth quarter of 2018. The HTG EdgeSeq Mouse miRNA WTA is designed for use with disease mouse models, including oncology, to identify and quantify the expression of a wide range of miRNAs in a variety of sample types, including formalin‑fixed paraffin-embedded tissue.

Appointed Dr. Maureen T. Cronin as HTG’s new Chief Scientific Officer and Senior Vice President in November 2018. Dr. Cronin brings extensive experience in genomic technology, laboratory test and pharmaceutical company therapeutics development, as well as regulatory compliance and academic clinical research to HTG.

Third Quarter 2018 Financial Results:

Total revenue for the third quarter of 2018 was $4.7 million, an increase of 26% over the same period in the prior year and included product and product-related services revenue of $1.3 million and collaborative development services revenue of $3.4 million. Revenue for the third quarter of 2017 included product and product-related services revenue of $1.6 million and collaborative development services revenue of $2.1 million.

Net loss from operations for the third quarter of 2018 was $4.8 million compared to $5.4 million for the same period in the prior year. Net loss per share was $(0.17) for the third quarter of 2018 compared to $(0.46) for the same period in the prior year.

HTG ended the third quarter of 2018 with $33.8 million of cash, cash equivalents and short term, available-for-sale securities investments.

2018 Revenue Guidance:

The company believes that its total revenue for the full year ending December 31, 2018 will be in the middle of the range of its previous full year 2018 revenue guidance of $21.0 to $25.0 million.

HTG is focused on next generation sequencing (NGS) based molecular profiling. The company’s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTG’s customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options. The company’s mission is to empower precision medicine at the local level.

Safe Harbor Statement:

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our Precision Immuno-Oncology Paneland planned HTG EdgeSeq Mouse miRNA Whole Transcriptome Assay, and our revenue and operational expectations. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based upon management’s current expectations, are subject to known and unknown risks, and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation, the risk that the Precision Immuno-Oncology panel may not function or provide benefits to our customers as expected, the risk that the HTG EdgeSeq Mouse miRNA Whole Transcriptome Assay may not be available when expected or provide benefits to our customers as expected, the risk that we may not achieve our revenue expectations for 2018 (including, without limitation, due to variations from our expectations in the amount or timing of work we perform under one or more companion diagnostic development programs with large pharma customers, which development programs comprise an increasing portion of our business and therefore have the ability to significantly impact the timing and amount of revenue recognized in one or more fiscal periods), the risk that we may not realize the benefits expected under our collaboration agreements, risks associated with our ability to successfully commercialize our products; the risk that our products and services may not be adopted by biopharmaceutical companies or other customers as anticipated, or at all; our ability to manufacture our products to meet demand; the level and availability of third party payor reimbursement for our products; our ability to effectively manage our anticipated growth; our ability to protect our intellectual property rights and proprietary technologies; our ability to operate our business without infringing the intellectual property rights and proprietary technology of third parties; competition in our industry; additional capital and credit availability; our ability to attract and retain qualified personnel; and product liability claims. These and other factors are described in greater detail in our filings with the Securities and Exchange Commission, including without limitation our Quarterly Report on Form 10-Q for the quarter ended June 30, 2018. All forward-looking statements contained in this press release speak only as of the date on which they were made, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

-Financial tables follow-

HTG Molecular Diagnostics, Inc.

Condensed Statements of Operations

(Unaudited)

Three Months Ended September 30,

Nine Months Ended September 30,

2018

2017

2018

2017

Revenue:

Product and product-related services

$

1,314,844

$

1,592,790

$

5,071,702

$

4,422,304

Collaborative development services

3,391,534

2,130,694

8,704,094

2,433,105

Total revenue

4,706,378

3,723,484

13,775,796

6,855,409

Cost of revenue

1,239,702

1,088,987

3,827,447

3,621,193

Gross margin

3,466,676

2,634,497

9,948,349

3,234,216

Operating expenses:

Selling, general and administrative

4,709,885

4,258,347

15,132,468

12,910,251

Research and development

3,561,459

3,478,419

8,909,729

6,364,371

Total operating expenses

8,271,344

7,736,766

24,042,197

19,274,622

Operating loss

(4,804,668

)

(5,102,269

)

(14,093,848

)

(16,040,406

)

Loss on settlement of Growth Term Loan

—

—

(105,064

)

—

Other expense, net

(38,740

)

(277,834

)

(123,627

)

(996,593

)

Net loss before income taxes

(4,843,408

)

(5,380,103

)

(14,322,539

)

(17,036,999

)

Provision for income taxes

—

743

3,545

1,023

Net loss

$

(4,843,408

)

$

(5,380,846

)

$

(14,326,084

)

$

(17,038,022

)

Net loss per share, basic and diluted

$

(0.17

)

$

(0.46

)

$

(0.53

)

$

(1.74

)

Shares used in computing net loss per share, basic and diluted

28,434,406

11,603,617

27,184,968

9,794,651

HTG Molecular Diagnostics, Inc.

Condensed Balance Sheets

September 30,

December 31,

2018

2017

Assets

(Unaudited)

Current assets:

Cash and cash equivalents

$

6,164,005

$

9,968,600

Short-term investments available-for-sale, at fair value

27,613,031

—

Accounts receivable

3,361,333

6,356,268

Inventory, net of allowance of $39,403 at September 30, 2018 and $62,142 at December 31, 2017

1,129,092

1,180,521

Prepaid expenses and other

688,556

443,068

Total current assets

38,956,017

17,948,457

Restricted cash - non-current

3,270,247

—

Deferred offering costs

—

2,953

Deferred MidCap revolving loan costs

71,126

—

Property and equipment, net

2,614,620

3,304,890

Total assets

$

44,912,010

$

21,256,300

Liabilities and stockholders' deficit

Current liabilities:

Accounts payable

$

1,867,181

$

2,438,798

Accrued liabilities

2,530,615

3,746,786

Contract liabilities - current

273,763

665,882

NuvoGen obligation - current

593,860

496,442

Growth Term Loan payable - net of discount and debt issuance costs

—

5,793,599

Other current liabilities

199,621

200,460

Total current liabilities

5,465,040

13,341,967

NuvoGen obligation - non-current, net of discount

6,684,631

7,520,913

Convertible note, related party - net of debt issuance costs

2,970,850

2,960,760

MidCap Term Loan payable - net of discount and debt issuance costs

6,666,796

—

Other non-current liabilities

333,367

492,197

Total liabilities

22,120,684

24,315,837

Commitments and Contingencies (Note 14)

Stockholders’ equity (deficit):

Common stock, $0.001 par value; 200,000,000 shares authorized at September 30, 2018 and December 31, 2017, 28,479,341 shares issued and outstanding at September 30, 2018 and 13,929,763 shares issued and outstanding at December 31, 2017